GSK plc
LONDON, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 5, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$497.0M2026 Q3
Positions13
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.98.1%
What Changed This Quarter?
Top Holdings
CRSP
CRISPR Therapeutics
29.0%
VIR
Vir Biotechnology
19.2%
WVE
Wave Life Sciences
13.6%
BNTX
BioNTech
13.2%
IDYA
IDEAYA Biosciences
10.3%
CYTK
Cytokinetics
4.5%
LYEL
Lyell Immunopharma
3.0%
SPRO
Spero Therapeutics
2.2%
Reduced / Exited
2 reduced · 1 sold out
CRSP
Crispr Therapeutics
29.0%
-19.0%
BNTX
BioNTech
13.2%
-24.9%
96663EUREXIT
Wave Life Sciences
17.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.